CDK
Los inhibidores de las quinasas dependientes de ciclina (CDK) son compuestos que bloquean la actividad de las CDK, un grupo de quinasas de proteínas que regulan el ciclo celular, la transcripción y otros procesos celulares. Las CDK se activan al unirse a las ciclinas, y su actividad es crucial para la progresión de las células a través de las diferentes fases del ciclo celular. Inhibir las CDK puede detener la división celular, provocando la detención del ciclo celular y la apoptosis, especialmente en células cancerosas donde las CDK a menudo están desreguladas. Los inhibidores de CDK se utilizan ampliamente en la investigación del cáncer y tienen un potencial terapéutico en el tratamiento de varios tipos de cáncer. En CymitQuimica, ofrecemos una selección completa de inhibidores de CDK de alta calidad para apoyar su investigación en el control del ciclo celular, el cáncer y el desarrollo terapéutico.
Se han encontrado 546 productos de "CDK"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
CGP60474
CAS:CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.Fórmula:C18H18ClN5OPureza:98.81%Forma y color:SolidPeso molecular:355.82Ref: TM-T14943
1mg34,00€2mg46,00€5mg71,00€10mg92,00€25mg177,00€50mg314,00€100mg518,00€1mL*10mM (DMSO)78,00€CDK9-IN-15
CAS:CDK9-IN-15: potent CDK9 inhibitor, blocks P-TEFb phosphorylation, inhibits transcription, reduces mRNA, induces tumor cell apoptosis.Fórmula:C16H11N3OSPureza:99.32%Forma y color:SolidPeso molecular:293.34Ref: TM-T60619
5mg46,00€10mg71,00€25mg126,00€50mg180,00€100mg260,00€200mg364,00€1mL*10mM (DMSO)44,00€Atuveciclib S-Enantiomer
CAS:Atuveciclib S-Enantiomer is a (S)-form of BAY-1143572; a potent, selective CDK9 inhibitor with an IC50 of 16 nM.Fórmula:C18H18FN5O2SPureza:98%Forma y color:SolidPeso molecular:387.43CDK2-IN-13
CAS:CDK2-IN-13: Potent CDK2 inhibitor, arrests cell cycle, induces apoptosis, IC50=12 µM, used in cancer research.Fórmula:C13H12ClN5Forma y color:SoildPeso molecular:273.72NSC 625987
CAS:NSC 625987, Selective CDK4 inhibitor (IC50=0.2 μM), >500-fold selectivity over CDK2, used for p16-associated tumor studies.Fórmula:C15H13NO2SPureza:98%Forma y color:SolidPeso molecular:271.33Ref: TM-T23092
1mg63,00€2mg105,00€5mg137,00€10mgA consultar25mgA consultar50mg595,00€100mg893,00€1mL*10mM (DMSO)A consultarARN22089
CAS:ARN22089 is an oral active CDC42 GTPase interaction inhibitor that blocks tumour growth in BRAF mutant mouse melanoma models and PDXs in vivo.Fórmula:C23H27N5Pureza:98.37%Forma y color:SolidPeso molecular:373.49Ref: TM-T85727
1mg109,00€5mg260,00€10mg385,00€25mg647,00€50mg964,00€100mg1.431,00€200mg1.963,00€1mL*10mM (DMSO)286,00€Cdc7-IN-4
CAS:Cdc7-IN-4 is a potent inhibitor of Cdc7 kinase.Fórmula:C22H24F3N5O4Pureza:98%Forma y color:SolidPeso molecular:479.45BAY-958
CAS:BAY-958 is a potent and selective inhibitor of PTEFb/CDK9.Fórmula:C17H16FN5O3SPureza:98%Forma y color:SolidPeso molecular:389.4TP1287
CAS:TP-1287 is an oral phosphate prodrug of the CDK9 inhibitor, alvocidib.Fórmula:C21H21ClNO8PForma y color:SolidPeso molecular:481.82Aloisine A
CAS:Aloisine A, a CDK/GSK-3 inhibitor with IC50: Cdk1/B-150nM, Cdk2/A-120nM, Cdk2/E-400nM, Cdk5/25-200nM, Cdk5/35-160nM, GSK-3α-500nM, GSK-3β-650nM, JNK-3-10μM.Fórmula:C16H17N3OPureza:98%Forma y color:SolidPeso molecular:267.33CLK1-IN-2
CLK1-IN-2: Metabolically stable, Clk1-selective inhibitor; IC50=1.7nM; useful in tumor, Duchenne MD, HIV-1, influenza research.Fórmula:C16H12Cl2N2O2SForma y color:SolidPeso molecular:367.25CDK4/6-IN-8
CAS:CDK4/6-IN-8 (Compound 7p) is a selective inhibitor of CDK4 (IC50=5.01 nM) and CDK6 (IC50=3.97 nM).Fórmula:C18H18N6O5Forma y color:SolidPeso molecular:398.37NSC 693868
CAS:CDKs and GSK-3 inhibitorFórmula:C9H7N5Pureza:98%Forma y color:SolidPeso molecular:185.19(E/Z)-BIO-acetoxime
CAS:(E/Z)-BIO-acetoxime: potent GSK-3 α/β inhibitor; IC50: GSK-3α/β 10nM, CDK5/p25 2.4μM, CDK2/A 4.3μM, CDK1/B 63μM.Fórmula:C18H12BrN3O3Forma y color:SolidPeso molecular:398.21MFH290
CAS:MFH290 is a selective CDK12/13 inhibitor, covalently bonding with CDK12 Cys-1039, blocks Pol II CTD phosphorylation, and enhances olaparib's efficacy.Fórmula:C26H31N5O3S2Forma y color:SolidPeso molecular:525.69RP-106
CAS:RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3.Fórmula:C17H19N3OPureza:98%Forma y color:SolidPeso molecular:281.35CDK8-IN-10
CAS:CDK8-IN-10 is a selective and potent inhibitor of cell cycle protein-dependent kinase (CDK8) (IC50: 8.25 nM) that can be used to study cancer.Fórmula:C25H15ClF3N5O3Forma y color:SolidPeso molecular:525.87CDK4/6-IN-12
CAS:CDK4/6-IN-12 inhibits CDK4/6 with IC50s of 592.3 nM & 3090 nM, useful in cancer research.Fórmula:C12H10N6Forma y color:SolidPeso molecular:238.25CCT068127
CAS:CCT068127 is a potent CDK2 and CDK9 inhibitor.Fórmula:C19H27N7OForma y color:SolidPeso molecular:369.46(S)-CR8
CAS:(S)-CR8 is an effective second-generation cyclin-dependent kinase inhibitor.Fórmula:C24H29N7OForma y color:SolidPeso molecular:431.53(S)-LY3177833 hydrate
CAS:(S)-LY3177833 ((S)-Example 2) hydrate, an orally active CDC7 kinase inhibitor, exhibits extensive in vitro anticancer efficacy.Fórmula:C16H14FN5O2Forma y color:SolidPeso molecular:327.31EGFR/HER2/CDK9-IN-2
CAS:EGFR/HER2/CDK9-IN-2 inhibits EGFR, HER2, CDK9 with IC50s: 145.35, 129.07, 117.13 nM; strong antitumor effects.Fórmula:C23H20N4O5S2Forma y color:SolidPeso molecular:496.56Cdc7-IN-9
CAS:Cdc7-IN-9 can be used for the research of cancer which is a potent inhibitor of Cdc7 [1].Fórmula:C15H17N5OSForma y color:SolidPeso molecular:315.39Cdc7-IN-14
CAS:Cdc7-IN-14 (compound 82) is a potent CDC7 inhibitor with an IC50 < 1 nM, promising for cancer research.Fórmula:C18H20N4O2SForma y color:SolidPeso molecular:356.44KH-CB19
CAS:KH-CB19 is an effective and highly specific inhibitor of the CDC2-like kinase isoforms 1 and 4 (CLK1/CLK4).Fórmula:C15H13Cl2N3O2Forma y color:SolidPeso molecular:338.19Ref: TM-T15657
2mgA consultar5mgA consultar25mgA consultar50mgA consultar100mgA consultar1mL*10mM (DMSO)A consultarCDK8-IN-6
CAS:CDK8-IN-6 (compound 9) is a potent inhibitor of cyclin-dependent kinase 8 (CDK8) (Kd: 13 nM), CDK8-IN-6 showed potential research value in AML cancers.Fórmula:C26H37ClN2Forma y color:SolidPeso molecular:413.04Ipivivint
CAS:Ipivivint: orally active, potent CLK inhibitor; hinders CLK1, CLK2, & CLK3; curbs Wnt signaling & SRSF phosphorylation for cancer research.Fórmula:C26H21FN8Forma y color:SolidPeso molecular:464.5FN-1501-propionic acid
CAS:FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.Fórmula:C25H27N9O4Pureza:98%Forma y color:SolidPeso molecular:517.54Cdc7-IN-3
CAS:Cdc7-IN-3 is a potent inhibitor of Cdc7 kinase.Fórmula:C20H22N4O5Pureza:98%Forma y color:SolidPeso molecular:398.41JTK-101
CAS:JTK-101 is a potent and selective Tat-dependent HIV-1 replication inhibitor.Fórmula:C25H23N3O3Forma y color:SolidPeso molecular:413.47Ulecaciclib
CAS:Ulecaciclib: oral, BBB-permeable CDK inhibitor; favorable pharmacokinetics; ki: 0.62 μM (CDK2/A), 3 nM (CDK6/D3), 0.2 nM (CDK4/D1), 0.63 μM (CDK7/H).Fórmula:C25H33FN8SForma y color:SolidPeso molecular:496.65Cdc7-IN-13
CAS:Cdc7-IN-13 (compound 84) is a highly potent CDC7 inhibitor, exhibiting an IC50 value of <1 nM. This compound holds promise for cancer research [1].Fórmula:C18H20N4O2SForma y color:SolidPeso molecular:356.44CDK4/6-IN-9
CAS:CDK4/6-IN-9 selectively inhibits CDK4/6 (IC50: 905 nM); potential for MM research.Fórmula:C22H23FN8Forma y color:SolidPeso molecular:418.47CDK1-IN-1
CAS:CDK1-IN-7 inhibits CDK1 at 161.2 nM, triggers p53-dependent apoptosis, and selectively targets tumor growth.Fórmula:C27H23N5O3Forma y color:SolidPeso molecular:465.5Indirubin-5-sulfonate
CAS:Indirubin-5-sulfonate inhibits GSK-3β & CDKs with IC50: 55/35/150/300/65 nM for CDK1/B, 2/A&E, 4/D1, 5/p35.Fórmula:C16H10N2O5SPureza:98%Forma y color:SolidPeso molecular:342.33CDK7-IN-8
CAS:CDK7-IN-8 is a potent inhibitor of CDK7 (IC50: 54.29 nM) and exhibits inhibitory activity against several cancer cells and in vivo tumor models.Fórmula:C25H38N8O3Forma y color:SolidPeso molecular:498.62FLT3/CDK4-IN-1
CAS:FLT3/CDK4-IN-1: Oral FLT3 (7 nM IC50) & CDK4 (11 nM IC50) inhibitor with strong in vivo anti-cancer properties.Fórmula:C25H28F2N8Forma y color:SolidPeso molecular:478.54CDK7-IN-20
CDK7-IN-20: potent, irreversible CDK7 inhibitor, IC50 of 4nM, 206x selectivity vs. other CDKs, potential for ADPKD study.Fórmula:C30H26N6O3Forma y color:SolidPeso molecular:518.57CDK7-IN-13
CAS:CDK7-IN-13 (compound 1) is an effective CDK7 inhibitor for investigating cancers associated with transcriptional dysregulation.Fórmula:C20H23F3N6OSPureza:99.22%Forma y color:SolidPeso molecular:452.5Indirubin-3'-monoxime-5-sulphonic acid
CAS:Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively.Fórmula:C16H11N3O5SPureza:98%Forma y color:SolidPeso molecular:357.34BSJ-01-175
CAS:BSJ-01-175: Selective, potent covalent inhibitor of CDK12/13, targets cancer cells, inhibits phosphorylated RNA polymerase II, downregulates CDK12 genes.Fórmula:C30H33ClN6O2Forma y color:SolidPeso molecular:545.08MDK6204
CAS:MDK6204 is a selective inhibitor of CLK1 and CLK2.Fórmula:C20H20N6OPureza:98%Forma y color:SolidPeso molecular:360.41XIE18-6
CAS:XIE18-6 is a novel INK4C inhibitor that blocks p18 activity and promotes ex vivo expansion of human and murine hematopoietic stem cells.Fórmula:C18H15NO6SPureza:99.712%Forma y color:SolidPeso molecular:373.38CDK4/6-IN-14
CAS:CDK4/6-IN-14: potent CDK4/6 inhibitor, IC50s 10/16 nM, >60-fold selectivity over CDKs 1/2/7/9, selective across 205 kinases.Fórmula:C24H27ClFN7OForma y color:SolidPeso molecular:483.97EGFR/HER2/CDK9-IN-1
CAS:EGFR/HER2/CDK9-IN-1 is a potent inhibitor (IC50: EGFR 90.17 nM, HER2 131.39 nM, CDK9 67.04 nM) with notable anti-tumor activity.Fórmula:C23H21N3O3S2Forma y color:SolidPeso molecular:451.56CDK7-IN-2
CAS:CDK7-IN-2 inhibits CDK7, essential for RNA polymerase II activation and cell cycle control, with cancer research potential.Fórmula:C26H39N7O3Forma y color:SolidPeso molecular:497.63CDK4/6-IN-7
CAS:CDK4/6-IN-7 is an oral, potent CDK4/6 inhibitor with IC50s of 1.58/4.09 nM, crucial for breast cancer studies.Fórmula:C18H18ClN5O3Forma y color:SolidPeso molecular:387.82CDK7-IN-12
CAS:CDK7-IN-12 inhibits CDK7 to control transcription and cell cycle, halting tumor growth in vitro/vivo with cancer research potential.Fórmula:C20H19F3N6Forma y color:SolidPeso molecular:400.4Crozbaciclib fumarate
CAS:Crozbaciclib fumarate is a CDK4/6 inhibitor with IC 50 s of 3 and 1 nM, respectively.Fórmula:C32H34F2N6O4Forma y color:SolidPeso molecular:604.65EGFR/CDK2-IN-1
CAS:EGFR/CDK2-IN-1, an inhibitor of both EGFR and CDK2, demonstrates effective cytotoxicity towards MCF7 and HepG2 cells, suggesting its potential application inFórmula:C19H12BrClO2Forma y color:SolidPeso molecular:387.65
